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INTRODUCTION
Neoadjuvant chemotherapy (NC) has traditionally been re-
garded as the standard for care in patients with locally advanced 
breast cancer with the purpose of achieving both local and sys-
temic control [1-4]. In recent years, with the advent of more ef-
fective chemotherapeutic drugs, NC is being administered to 
patients with operable breast cancer with the aim of breast 
conservation after shrinkage of the primary tumor [5,6]. An-
other advantage of NC is that it can be used as an in vivo che-
mosensitivity test, allowing for a rapid individual evaluation 
of a regimen [7]. Local clinical response to NC might also be a 
predictor of response to distant micrometastases and eventual 
outcome. Prognostic factors are important for clinical decision 
making and for tailoring treatment of individual patients with 
cancer. Axillary lymph node (ALN) status is the single most 
reliable prognostic indicator of early breast cancer, followed by 
primary tumor size. However, downstaging of both the prima-
ry tumor and ALN involvement by NC results in a loss of tradi-
tional prognostic factors. With increased use of NC, outcomes 
must be predicted to provide tailored treatment for patients 
treated with NC. Only a few studies have investigated concern-
ing the prognostic factors related to long term survival in pa-
tients with operable breast cancer treated with NC. In 2000, 
the results of a phase II trial were published for 73 patients with 
stage II/III breast cancer, comparing FEC (5-FU, epirubicin, 
and cyclophosphamide) and MMM (mitoxantrone, metho-
rtexate, and mitomycin) in the Journal of the Korean Surgical 
Society [8]. The aim of this retrospective study was to identify 
the reliable long-term prognostic factors in patients with stage 
II/III breast cancer treated with an adjuvant extension of NC. 
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Purpose: The aim of this retrospective study was to identify the 
reliable long term prognostic factors in patients with stage II/III 
breast cancer who were treated with an adjuvant extension of 
neoadjuvant chemotherapy (NC). Methods: Women under the 
age of 70-years, with previously untreated clinical stage II and III 
breast cancer, were treated with NC, which was comprised of 
three cycles of FEC (5-FU, epirubicin, and cyclophosphamide 
every 3 weeks) or MMM (methotrexate, mitoxantrone, and mito-
mycin-C every 3 weeks) with an adjuvant extension of three cycles 
of the same regimen. Results: Cumulative 10-years disease-free 
survival (DFS) was 87.3% for patients with a good response and 
55.5% for patients with no response (p=0.032); 92.9% for node 
negative patients, 75.0% for 1-3 positive nodes, 50.0% for 4-9 
positive nodes and no survival for 10 or more positive nodes (p< 
0.001). Cumulative 10-years overall survival (OS) was 89.1% for 
patients with good response and 55.5% for patients with no re-
sponse (p=0.024); 95.2% for node negative patients, 80.0% for 
1-3 positive nodes, 50.0% for 4-9 positive nodes and no survival 
for 10 or more positive nodes (p<0.001). No significant difference 
was observed in DFS and OS between the FEC and MMM treat-
ed groups. Conclusion: Based on a review of data with a long fol-
low-up, only the clinical response to NC and the absolute number 
of metastatic axillary lymph node identified at surgical staging were 
independent predictors of both DFS and OS in patients with stage 
II/III breast cancer patients treated with adjuvant extension of NC.
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METHODS
Eligibility criteria
Women under the age of 70-years with previously untreated 
clinical stage II and III breast cancer, who had suspicious ALN 
involvement or tumors larger than 3 cm, were eligible for the 
study according to the American Joint Committee on Cancer 
5th edition. The Institutional Review Board approved the study 
(IRB: 1002-19), and all patients provided written informed 
consent. Other eligibility criteria included adequate perfor-
mance status (Eastern Cooperative Oncology Group [ECOG] 
performance status ≤1); adequate hematology (hemoglobin, 
≥10 g/dL; absolute neutrophil count, ≥1.5×10
9/L; and plate-
lets, ≥100×10
9/L), renal (serum creatinine, ≤1.5 upper nor-
mal limits), and liver (AST, ALT, and alkaline phosphatase all 
≤1.5×upper limit of normal, and bilirubin within normal 
limits) function; and have no evidence of metastatic disease. 
Patients were excluded if there was any evidence of active car-
diac disease or a history of malignancy at another site.
Treatment scheme
Patients were treated with NC comprised of three cycles of 
FEC (500 mg/m
2 5-FU, 75 mg/m
2 epirubicin, 500 mg/m
2 cy-
clophosphamide every 3 weeks) or MMM (40 mg/m
2 metho-
trexate, 8 mg/m
2 mitoxantrone, 8 mg/m
2 mitomycin-C every 
3 weeks) with an adjuvant extension of three cycles of the same 
regimen. The regimen was chosen according to patient’s own 
preference with regard to alopecia. The clinical response was 
assessed after two consecutive cycles of preoperative chemo-
therapy. An early operation was performed 2-3 weeks after dis-
continuing the chemotherapy for resectable tumors in cases of 
tumor progression after two cycles of preoperative chemother-
apy. All patients underwent ALN dissection either with mas-
tectomy or lumpectomy. After operative treatment, adjuvant 
chemotherapy was administered with three cycles of the same 
regimen for those who achieved objective clinical response, 
but six cycles of switching regimen, either FEC or MMM, were 
administered for those who had stable disease or progression 
(Figure 1). Radiation therapy began within 4 weeks after the 
last cycles of chemotherapy, if indicated. Tamoxifen was ad-
ministered after the chemo-radiation for 5 years when the hor-
mone receptor was positive. 
Evaluation of clinical response and toxicity 
Clinical response was assessed by a physical examination 
and ultrasonography for bidimensionally measurable disease 
according to standard Union Internationale Contra le Cancer 
(UICC) criteria. During the physical examination, we used a 
transparent grid for mapping the extent of the tumor at the 
beginning and again after the two cycles of NC. A clinical com-
plete response (cCR) was defined as the disappearance of all 
known disease and a clinical partial response (cPR) was de-
fined as reduction of 50% or greater in the product of the two 
largest perpendicular dimensions of the primary lesion. Pro-
gressive disease (PD) was defined as an increase of more than 
25% in the product of the two largest perpendicular dimen-
sions of the primary tumor or the appearance of new lesions. 
Stable disease (SD) was represented by a less than 50% decrease 
or a less than 25% increase in the product of the two largest 
perpendicular dimensions of the primary tumor. A pathologi-
cal complete response (pCR) was defined as no residual tumor 
cells in the breast and axilla based on histopathology of the 
operative specimens following NC. The number of involved 
ALN was recorded from the axillary dissection specimen by 
the pathologist. Toxicity was graded according to the ECOG 
common toxicity criteria. 
Survival analysis 
Overall survival (OS) and disease-free survival (DFS) were 
considered from the onset of NC and from the day of surgery, 
respectively. A statistical analysis was conducted using the SPSS 
version 12.0 (SPSS Inc., Chicago, USA). A univariate survival 
analysis was performed with the Kaplan-Meier method, and 
comparisons between curves were performed with the log-
rank test. Factors were entered into a Cox multivariate regres-
sion model to analyze the potential simultaneous effect of the 
significant predictors of DFS and OS identified by the univari-
Figure 1. Treatment scheme of chemotherapy. FEC=5-FU+epirubicin+ 
cyclophosphamide; MMM=methotrexate+mitoxantrone+mitomycin-C.
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ate analysis. Patient follow-up was performed in the clinic un-
til either death or the patient’s last visit on or before December 
2007 in both the FEC and MMM groups. Survival data were 
provided by the Korea National Statistical Office for those un-
available for follow-up. 
RESULTS
Patient characteristics 
From February 1991 to October 1998, seventy three pa-
tients diagnosed with breast cancer, with a tumor size ≥3 cm 
or clinically axillary node positive, were enrolled for the phase 
II trial. Patients with known distant metastases were excluded. 
The mean age of patients was 45.5±1.2 years (range, 27-69). 
The median follow-up period was 135 months (range, 6-186). 
The clinical characteristics of the patients are shown in Table 1. 
No significant difference was observed with regard to clinico-
pathological parameters between the FEC and MMM groups.
Clinical response and toxicity
An overall objective clinical response was observed in 75.4% 
(cCR, 19.2%; cPR, 56.2%) of the patients including nine cases 
(12.3%) of pCR (Table 1). The remaining 24.6% showed SD 
(21.9%) and PD (2.7%), respectively. Pretreatment tumor size 
and age were significantly related to clinical response to NC 
(Table 2). Smaller tumors showed a better response to NC than 
larger tumors (p=0.001). Patients older than 35-years of age 
showed a better response to NC than younger patients (p= 
0.047). No significant difference was observed with regard to 
clinical response to NC between the FEC and MMM groups. 
According to the ECOG common toxicity criteria, no signifi-
cant difference was observed with regard to grade 3/4 severe 
toxicities. Reversible alopecia and mild to moderate nausea 
were more common in the FEC group than in the MMM group.
Prognostic factors affecting DFS and OS
A univariate analysis showed that initial tumor stage, patho-
logical ALN status, and clinical response were prognostic fac-
tors of DFS and OS. Additionally, pathological tumor stage 
was associated with OS in the univariate analysis. However, a 
multivariate analysis indicated that DFS and OS were signifi-
cantly related to the clinical response and the number of in-
volved ALNs (Table 3). Cumulative 10-year DFS was 87.3% 
Table 1. Clinical characteristics of patients (n=73) 
Characteristics No. (%)
Age (yr) 45.5±1.2 (27-69)*
Follow-up (mo) 135 (6-186)
†
Menopausal status
   Premenopause
   Postmenopause
  
52 (71.2)
21 (28.8)
Chemotherapeutic regimen
   FEC
   MMM
 
30 (41.1)
43 (58.9)
Initial tumor size (cm)
   ≤2 
   >2, ≤5 
   >5
  
20 (27.4)
43 (58.9)
10 (13.7)
Operation
   Mastectomy
   BCO
  
26 (35.6)
47 (64.4)
Radiotherapy
   Yes
   No
  
54 (74.0)
19 (26.0)
Clinical response to chemotherapy
   Complete response (pathological)
   Partial response 
   Stable disease 
   Progressive disease 
  
14 (19.2)
  9 (12.3)
41 (56.2)
16 (21.9)
2 (2.7)
SE=standard error; FEC=fluorouracil+epirubicin+cyclophosphamide; MMM= 
mitoxantrone+methotrexate+mitomycin; BCO=breast conserving operation.
*Mean±SE (range); 
†Median (range).
Table 2. Significance of various factors on clinical response to chemo-
therapy
Response
Total 
(n=73)
p-value* CR/PR,  
No. (%)  
(n=55)
SD/PD,  
No. (%) 
(n=18)
Age (yr)
   ≤35 
   >35 
 
5 (50.0)
50 (79.4)
 
5 (50.0)
13 (20.6)
 
10
63
0.047
Menstrual status
   Premenopause
   Postmenopause
 
39 (75.0)
16 (76.2)
 
13 (25.0)
5 (23.8)
 
52
21
NS
Chemotherapeutic  
   regimen
   FEC
   MMM
 
24 (80.0)
31 (72.1)
 
6 (20.0)
12 (27.9)
 
30
43
NS
Histopathologic type
   Invasive NOS
   Special type
 
42 (71.2)
13 (92.9)
 
17 (28.8)
1 (7.1)
 
59
14
0.093
Initial tumor size (cm)
   ≤2 
   >2, ≤5 
   >5
 
18 (90.0)
34 (79.1)
3 (30.0)
2 (10.0)
9 (20.9)
7 (70.0)
 
20
43
10
0.001
Pathologic axillary  
   nodal status
   0
   1-3
   >4
 
36 (85.7)
14 (70.0)
 5 (45.5)
 
6 (14.3)
6 (30.0)
6 (54.5)
 
42
20
11
0.005
Operation 
   Mastectomy
   BCO
 
12 (46.2)
43 (91.5)
 
14 (53.8)
4 (8.5)
 
26
47
0.000
CR=complete response; PR=partial response; SD=stable disease; PD=pro-
gressive disease; NS=not significant; FEC=fluorouracil, epirubicin, cyclophos-
phamide; MMM=mitoxantrone, methotrexate, mitomycin; NOS=not other-
wise specified; BCO=breast conserving operation.
*Linear-by-linear association. 42  JeryongKim,etal.
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Table 3. Analysis of factors affecting disease-free survival rates (DFSR) and overall survival rates (OSR)
 Characteristics No. (%) 5-yr DFSR 
(%)
10-yr DFSR 
(%)
Univariate 
p-value*
Multivariate 
p-value
†
5-yr OSR 
(%)
10-yr OSR 
(%)
Univariate 
p-value*
Multivariate 
p-value
†
Menopausal status
   Premenopause
   Postmenopause
 
52 (71.2)
21 (28.8)
78.9
90.4
 
78.9
85.7
 
0.765
  
-
 
86.5
85.7
 
80.6
81.0
 
0.738
 
-
Type of chemotherapy
   FEC
   MMM
 
30 (41.1)
43 (58.9)
 
90.0
79.1
 
86.7
74.3
 
0.202 -
  
90.0
83.7
 
83.1
79.1
 
0.525
 
-
Operation
   Mastectomy
   BCO
 
26 (35.6)
47 (64.4)
 
69.2
91.5
 
65.4
87.1
  
0.043 0.483
 
65.4
93.5
 
57.7
93.5
 
0.000
 
0.094
Initial tumor stage 
   T1 
   T2
   T3
 
20 (27.4)
43 (58.9)
10 (13.7)
 
95.0
83.7
60.0
 
90.0
78.7
60.0
 
0.031
 
0.389
 
100
88.4
50.0
 
100
81.2
40.0
 
0.000
 
0.185
Pathologic tumor stage
   T0
   T1
   T2
   T3 
 
  9 (12.3)
33 (45.2)
26 (35.6)
  5 ( 6.8)
 
88.9
90.9
76.9
60.0
 
88.9
87.9
69.2
60.0
 
0.249
 
-
 
100
97.0
76.9
40.0
 
100
87.9
72.9
40.0
 
0.011
 
0.423
Pathologic ALN status
   0
   1-3
   4-9
   ≥10 
 
42 (57.5)
20 (27.4)
6 (8.2)
5 (6.8)
 
95.2
85.0
50.0
0
 
92.9
75.0
50.0
0
 
0.000
 
0.000
 
97.6
90.0
50.0
20.0
 
95.2
80.0
50.0
0
 
0.000
 
0.000
Histopathologic type
   Invasive NOS
   Special type
 
59 (80.8)
14 (19.2)
 
83.1
85.7
 
79.7
78.6
 
0.712
 
-
 
83.0
92.9
 
77.8
92.9
 
0.176
 
-
Differentiation
   Well
   Moderately
   Poorly
   NA 
 
24 (37.5)
27 (42.2)
13 (20.3)
9
 
87.5
85.2
84.6
 
79.1
81.5
76.9
 
0.751
 
-
 
87.5
77.8
84.6
 
83.3
74.1
76.9
 
0.432
 
-
Estrogen receptor
   +
   -
   NA 
 
32 (62.7)
19 (37.3)
22
 
90.6
57.9
 
78.1
57.9
 
0.334
 
-
 
96.8
64.3
 
84.3
64.3
 
0.134
 
-
Progesterone receptor
   +
   -
   NA 
 
19 (37.3)
32 (62.7)
22
 
89.5
78.1
 
73.7
78.1
 
0.867
 
-
 
100
78.1
 
78.9
75.0
 
0.621
 
-
Ki-67
   +
   -
   NA 
 
21 (41.2)
30 (58.8)
22
 
81.0
70.0
 
81.0
73.3
 
0.700
 
-
 
80.1
90.0
 
71.4
76.7
 
0.696
 
-
c-erbB2
   +
   -
   NA 
 
11 (21.6)
40 (78.4)
22
 
72.7
87.5
 
72.7
77.5
 
0.599
 
-
 
81.8
87.5
 
81.8
72.5
 
0.525
 
-
Triple negative cancer
   Yes
   No
   NA 
15 (29.4)
36 (70.6)
22
 
73.3
86.1
 
73.3
77.8
 
0.538
 
-
 
66.7
94.4
 
66.7
80.6
 
0.198
 
-
Clinical response 
   CR/PR
   SD/PD
 
55 (75.4)
18 (24.6)
 
90.9
61.1
87.3
55.5
0.003 0.032
 
96.4
55.5
 
89.1
55.5
 
0.000
 
0.024
EC=fluorouracil+epirubicin+cyclophosphamide; MMM=mitoxantrone+methotrexate+mitomycin; BCO=breast conserving operation; NOS=not otherwise speci-
fied; ALN=axillary lymph node; NA=not available; CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease.
*Log-rank test; 
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for patients with CR/PR, 55.5% for patients with SD/PD (p= 
0.032), 92.9% for node negative patients, 75.0% for patients 
with 1-3 positive nodes, 50.0% for patients with 4-9 positive 
nodes, and no survival for patients with 10 or more positive 
nodes (p<0.001, Figure 2). Cumulative 10-year OS was 89.1% 
for patients with CR/PR, 55.5% for patients with SD/PD (p= 
0.024), 95.2% for node negative patients, 80.0% for patients 
with 1-3 positive nodes, 50.0% for patients with 4-9 positive 
nodes, and no survival for patients with 10 or more positive 
nodes (p<0.001, Figure 3). No significant difference was ob-
served in DFS and OS between the FEC and MMM groups. 
Histopathological type, differentiation, hormone receptor, Ki-
67, c-erbB2, and triple negative cancer were not predictive of 
DFS or OS. All of these pathological findings and biological 
markers (hormone receptor, Ki-67, c-erbB2) were examined 
in postoperative specimens.
DISCUSSION 
The clinical characteristics of the patients were remarkable 
in terms of the high proportion of young premenopausal pa-
tients. The median age of the studied patients was far below 50 
years because breast cancer in Korean women tends to occur 
earlier than in Western countries, showing a peak incidence 
in the 40s [9]. In general, Korean women who have breast tu-
mors larger than 3 cm are not candidates for breast conserv-
ing operations because they have smaller breasts than those of 
women from western countries. NC for patients with breast 
cancer is currently used with the main aim of achieving path-
ological complete remission and improving survival. Second, 
it is used to conserve the breast and axilla due to tumor down-
staging. The main problem with NC is the loss of traditional 
prognostic markers such as tumor size or axillary LN status. 
pCR following NC is a well known powerful prognostic 
Figure 2. Disease-free survival (DFS) curves according to the clinical response to chemotherapy and pathological axillary lymph node (ALN) status us-
ing the Kaplan-Meier statistical method and the log-rank test. 
CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease.
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Figure 3. Overall survival curves according to the clinical response to chemotherapy and pathological axillary lymph node (ALN) status using the         
Kaplan-Meier statistical method and the log-rank test. 
CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease.
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marker for longer survival. Unfortunately, the vast majority of 
patients treated with NC will not have a pCR, and no guide-
lines exist for these patients. This is the most important prob-
lem in the field of NC and needs to be resolved through large 
randomized clinical trials to identify a tailored treatment. Two 
large randomized trials, the EORTC 10902 and the NSABP 
B-18, reported that clinical and pathological responses were 
be long term prognostic factors following NC. In a study from 
Korea, initial clinical stage, estrogen receptor, bcl-2, and triple 
negative phenotype were statistically significant variables 
which impacted on OS [10]. In our study, based on a review 
of data with a long follow-up, the clinical or pathological re-
sponse to neoadjuvant chemotherapy and the absolute num-
ber of metastatic ALNs identified at surgical staging were in-
dependent predictors of both DFS and OS. The clinical re-
sponse to NC was related to tumor size and age: tumor re-
sponse was more marked in smaller tumors and older patients 
≥35 years (Table 2). However, most groups have reported no 
influence of age or menopausal status on the response to che-
motherapy. Jacquillat et al. [11] reported that tumor response 
is inversely related to age. A cCR was achieved in 18% of pa-
tients less than 50 years of age compared to 37% of those who 
were over 50 years (p=0.007). It is well known that patients 
with large tumors are less likely to have a pCR compared to 
those with smaller tumors, because larger tumors tend to have 
decreased drug delivery by inefficient blood flow and relative-
ly high intratumoral pressure [12]. Achieving cCR without 
pCR following NC may be associated with partial eradication 
of the micrometastasis. pCR following NC is infrequent: 
12.3% in our series, 11% in the NSABP B-18 trial, and 4% in 
the EORTC trial 10902 [1,13,14]. In the current study, surgery 
was performed in all patients with cCR because of the reported 
significant increase in locoregional recurrences when only ra-
diotherapy was administered without surgery in the case of 
cCR [15]. As observed, tumor progression during NC is rare: 
2.7% in our series, 1.4% in the EORTC trial 10902, and 3% in 
the NSABP B-18 trial [1,13,14]. Results from NSABP B-18 
show no statistically significant differences in DFS and OS re-
garding sequencing chemotherapy preoperatively or postop-
eratively between the neoadjuvant and adjuvant groups. How-
ever, there were trends in favor of preoperative chemotherapy 
for DFS and OS in women under 50 years (hazard ratio [HR], 
0.85, p=0.090 for DFS; HR, 0.81, p=0.060 for OS). Five-year 
DFS also demonstrated a strong trend in favor of the neoadju-
vant group (HR, 0.81, p=0.053) [13]. Considering the relative-
ly younger age of the Korean patients with breast cancer as 
compared with women from Western countries, the benefit 
from NC might be more considerable for Korean patients 
with breast cancer than for women from Western countries. In 
the current study, chemotherapy was performed with an adju-
vant extension of NC for those whom achieved an objective 
clinical response to NC. According to the results of the in vivo 
chemosensitivity test, these patients could have better clinical 
outcome by changing the resistant chemotherapeutic regimen 
to a non-cross-resistant chemotherapeutic regimen. However, 
in the MDACC trial, the change to a non-cross-resistant regi-
men in an adjuvant setting did not improve the outcome for 
the patients with a poor response to NC [16]. The NSABP 
B-27 trial did not identify any group of patients who would 
benefit from adding neoadjuvant or adjuvant docetaxel che-
motherapy in patients who received four cycles of neoadju-
vant doxorubicin and cyclophosphamide [4,13]. In the B-27 
trial, treatment was not based on in vivo chemosensitivity test 
which was applied in the current study. Currently, the role of 
combining a neoadjuvant and adjuvant chemotherapy regi-
men is unclear. pCR rate, which is an indicator of good clini-
cal outcome, increases by adding neoadjuvant or adjuvant se-
quential taxane, or by adding more cycles of NC or a combi-
nation of trastuzumab with NC [4,13,17-20]. However, it is 
unclear whether these results will translate into an improve-
ment in survival. In the Nottingham experience, six cycles of 
preoperative FEC chemotherapy has resulted in a better re-
sponse and a significantly better outcome to six cycles of pre-
operative MMM chemotherapy [21]. However, in our study, 
neither clinical response nor long term clinical outcome were 
different between the FEC and MMM groups. This was possi-
bly due to the limitation of a smaller sample size and a differ-
ent treatment schedule. Generally, ALN status is regarded as 
the most important surrogate marker for patients with breast 
cancer, and ALN dissection is an integral part of the accepted 
management of breast cancer. NC completely eradicates axil-
lary metastatic disease in approximately 20% to 40% of pa-
tients before ALN dissection [4,13,22]. In the current study, neg-
ative ALN metastasis was significantly higher in the responsive 
group (36/55) than in the non-responsive group (6/18) (Table 
2). One study from M.D. Anderson suggests that axillary irra-
diation without ALN dissection may provide adequate local 
control in patients with at least a partial response of the pri-
mary tumor to NC and a clinically negative axilla [23]. Dav-
eau et al. [24] reported that omission of axillary irradiation in 
patients with no pathologic ALN involvement after NC re-
sulted in no increase in the risk of distant metastasis, locore-
gional recurrence, or death. Furthermore, ALN dissection can 
be avoided through sentinel LN biopsy after NC in virtually 
all patients and accurately selected patients who required com-
plete level I and II ALN dissection [25]. In terms of axillary 
treatment, the responsive group could have had more chance 
to avoid ALN dissection or irradiation than the non-respon-NeoadjuvantChemotherapyinStageII/IIIBreastCancer 45
DOI: 10.4048/jbc.2011.14.1.39  http://ejbc.kr
sive group. There has been some debate on the role of ALN 
status following NC as a prognostic factor [10,26]. Based on a 
review of data with a long follow-up, ALN status after NC was 
still the most powerful prognostic indicator followed by clini-
cal response in the current study. Thus, patients with partial 
or minor response following NC can be further stratified with 
respect to DFS and OS by the number of involved ALNs. 
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